Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 4, 2013, Pages 458-463

  Natesan, S Krishnan ^a,b   Lamichchane, A K ^a   Swaminathan, Subramanian ^a   Wu, Wenjuan ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspergillus flavus; Azole resistance; CCCP; Efflux pumps; FICI; MDR; MRNA transcripts; Oligomycina; Overexpression; QRT PCR; Voriconazole

Indexed keywords

ABC TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FLAVUS; CONTROLLED STUDY; DRUG EXPOSURE; FUNGAL CELL; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; WILD TYPE;

ASPERGILLUS FLAVUS; AZOLE-RESISTANCE; CCCP; EFFLUX PUMPS; FICI; MDR; MRNA TRANSCRIPTS; OLIGOMYCINA; OVEREXPRESSION; QRT-PCR; VORICONAZOLE;

ANTIFUNGAL AGENTS; ASPERGILLUS FLAVUS; BIOLOGICAL TRANSPORT; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; MICROBIAL SENSITIVITY TESTS; OLIGOMYCINS; P-GLYCOPROTEINS; PROTEIN ISOFORMS; PYRIMIDINES; RNA, FUNGAL; RNA, MESSENGER; TRIAZOLES;

EID: 84880716413     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.04.022     Document Type: Article

References (72)

1. Andrade A.C., Del Sorbo G., Waard M.A. The ABC transporter AtrB from Aspergillus nidulans mediates resistance to all major classes of fungicides and some natural toxic compounds. Microbiology 2000, 146(Pt 8):1987-1997.
2. Andrade A.C., Van Nistelrooy J.G., Peery R.B., De Waard M.A. The role of ABC transporters from Aspergillus nidulans in protection against cytotoxic agents and in antibiotic production. Mol Gen Genet 2000, 263(6):966-977.
3. Bille J., Marchetti O., Calandra T. Changing face of health-care associated fungal infections. Curr Opin Infect Dis 2005, 18(4):314-319.
4. Bowyer P., Mosquera J., Anderson M., et al. Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. FEMS Microbiol Lett 2012, 332(1):10-19.
5. Brun S., Fekkar A., Busse A., Seilhean D., Lecsö M., Adler D., et al. Aspergillus flavus brain abscesses associated with hepatic amebiasis in a non-neutropenic man in Senegal. Am J Trop Med Hyg 2009, 81(4):583-586.
6. Bueid A., Howard S.J., Moore C.B., Richardson M.D., Harrison E., Bowyer P., et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010, 65(10):2116-2118.
7. Camps S.M., van der Linden J.W., Li Y., Kuijper E.J., van Dissel J.T., Verweij P.E., et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012, 56(1):10-16.
8. Camps S.M., Dutilh B.E., Arendrup M.C., Rijs A.J., Snelders E., Huynen M.A., et al. Discovery of a hapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One 2012, 7(11):e50034.
9. Cesaro S., Toffolutti T., Messina C., Calore E., Alaggio R., Cusinato R., et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004, 73(1):50-55.
10. Chakrabarti A., Singh R. The emerging epidemiology of mould infections in developing countries. Curr Opin Infect Dis 2011, 24(6):521-526.
11. Chakrabarti A., Sharma S.C., Chandler J. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg 1992, 107(6 pt 10):745-750.
12. Chang H.M., Yu H.H., Yang Y.H., Lee W.I., Lee J.H., Wang L.C., et al. Successful treatment of Aspergillus flavus spondylodiscitis with epidural abscess in a patient with chronic granulomatous disease. Pediatr Infect Dis J 2012, 31(1):100-101.
13. Chen C.Y., Sheng W.H., Cheng A., Chen Y.C., Tsay W., Tang J.L., et al. Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan. BMC Infect Dis 2011, 11:250.
14. Chen L.M., Xu Y.H., Zhou C.L., Zhao J., Li C.Y., Wang R. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. J Int Med Res 2010, 38(2):536-545.
15. Chowdhary A., Kathuria S., Randhawa H.S., Gaur S.N., Klaassen C.H., Meis J.F. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012, 67(2):362-366.
16. Costa-de-Oliveira S., Araujo R., Silva-Dias A., Pina-Vaz C., Rodrigues A.G. Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell. BMC Microbiol 2008, 8:9.
17. Da Silva Ferreira M.E., Capellaro J.L., dos Reis Marques E., Malavazi I., Perlin D., Park S., et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother 2004, 48(11):4405-4413.
18. Del Sorbo G., Andrade A.C., Van Nistelrooy J.G., Van Kan J.A., Balzi E., De Waard M.A. Multidrug resistance in Aspergillus nidulans involves novel ATP-binding cassette transporters. Mol Gen Genet 1997, 254(4):417-426.
19. Denning D.W., Perlin D.S. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol 2011, 6(11):1229-1232.
20. Denning D.W., Park S., Lass-Florl C., Fraczek M.G., Kirwan M., Gore R., et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011, 52(9):1123-1129.
21. Escribano P., Recio S., Peláez T., González-Rivera M., Bouza E., Guinea J. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob Agents Chemother 2012, 56(1):174-178.
22. García-Agudo L., Aznar-Marín P., Galán-Sánchez F., García-Martos P., Marín-Casanova P., Rodríguez-Iglesias M. Otomycosis due to filamentous fungi. Mycopathologia 2011, 172(4):307-310.
23. Grossman M.E., Fithian E.C., Behrens C., Bissinger J., Fracaro M., Neu H.C. Primary cutaneous aspergillosis in six leukemic children. J Am Acad Dermatol 1985, 12(2 Pt 1):313-318.
24. Hadrich I., Makni F., Neji S., Abbes S., Cheikhrouhou F., Trabelsi H., et al. Invasive aspergillosis: resistance to antifungal drugs. Mycopathologia 2012, 174(2):131-141.
25. Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fisher M.C., Pasqualotto A.C., et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15(7):1068-1076.
26. Howard S.J., Arendrup M.C. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011, 49(Suppl 1):S90-S95.
27. Hiraga K., Yamamoto S., Fukuda H., Hamanaka N., Oda K. Enniatin has a new function as an inhibitor of Pdr5p, one of the ABC transporters in Saccharomyces cerevisiae. Biochem Biophys Res Commun 2005, 328(4):1119-1125.
28. Hsiue H.C., et al. Culture-positive invasive aspergillosis in a medical center in Taiwan, 2000-2009. Eur J Clin Microbiol Infect Dis 2011.
29. Iwen P.C., Rupp M.E., Hinrichs S.H. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis 1997, 24(6):1178-1184.
30. Izumikawa K., Takazono T., Kohno S. Chronic aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance. Curr Opin Infect Dis 2010, 23(6):584-589.
31. Jeurissen A., Cooreman S., Van Kerckhoven W., Van Leemput J., Vanhove P., Lagrou K., et al. Invasive pulmonary aspergillosis due to a multi-azole resistant Aspergillus fumigatus. Acta Clin Belg 2012, 67(1):46-48.
32. Kolaczkowska A., Kolaczkowski M., Delahodde A., Goffeau A. Functional dissection of Pdr1p, a regulator of multidrug resistance in Saccharomyces cerevisiae. Mol Genet Genomics 2002, 267(1):96-106.
33. Krishnan-Natesan S., Chandrasekar P.H., Alangaden G.J., Manavathu E.K. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents 2008, 32(6):519-524.
34. La Nasa G., Littera R., Maccioni A., Ledda A., Vacca A., Contu L. Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia. Hematol J 2004, 5(2):178-180.
35. Lionakis M.S., Lewis R.E., Torres H.A., Albert N.D., Raad I.I., Kontoyiannis D.P. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005, 52(1):15-20.
36. Liu W., Sun Y., Chen W., Liu W., Wan Z., Bu D., et al. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother 2012, 56(5):2598-2603.
37. López-Cortés L.E., et al. Invasive aspergillosis with extrapulmonary involvement: pathogenesis, clinical characteristics and prognosis. Rev Iberoam Micol 2011.
38. Maesaki S., Marichal P., Vanden Bossche H., Sanglard D., Kohno S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother 1999, 44(1):27-31.
39. Malani A.N., Kauffman C.A. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007, 67(13):1803-1812.
40. Manavathu E.K., Vasquez J.A., Chandrasekar P.H. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 1999, 12:213-219.
41. Mann P.A., Parmegiani R.M., Wei S.Q., Mendrick C.A., Li X., Loebenberg D., et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 2003, 47(2):577-581.
42. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
43. McNeil M.M., Nash S.L., Hajjeyh R.A., Phelan M.A., Conn L.A., Pkikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States. 1980-1997. Clin Infect Dis 2001, 33:641-647.
44. Mittal V., Mittal R., Sharma P.C. Voriconazole-refractory fungal infection of phacoemulsification tunnel. Indian J Ophthalmol 2010, 58(5):434-437.
45. Morschhäuser J. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 2010, 47(2):94-106.
46. Nascimento A.M., Goldman G.H., Park S., Marras S.A., Delmas G., Oza U., et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 2003, 47(5):1719-1726.
47. Nayak N., et al. Molecular characterization of drug-resistant and drug-sensitive Aspergillus isolates causing infectious keratitis. Indian J Ophthalmol 2011, 59(5):373-377.
48. Pasticci M.B., Barchiesi F., Fallani S., Palladino N., Lapalorcia L.M., Gubbiotti M., et al. Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. J Chemother 2006, 18(5):549-553.
49. Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012, 125(1 Suppl):S3-S13.
50. Pham C.D., Shawn R., Lockhart S.R. An invisible threat: mutation-mediated resistance to triazole drugs in Aspergillus. Curr Fungal Infect Rep 2012, 6:288-295.
51. Pyle J.W., et al. Multiple modality treatment regimen in an aggressive resistant fungal hand infection: a case report. Hand 2010, 5:318-321.
52. Rajendran R., Mowat E., McCulloch E., Lappin D.F., Jones B., Lang S., et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother 2011, 55((5):2092-2097.
53. Ram Reddy C., Ram R., Swarnalatha G., Krishna L.S., Prayaga A., Murthy P.V., et al. "True" mycotic aneurysm of the anastomotic site of the renal allograft artery. Exp Clin Transplant 2012, 10(4):398-402.
54. Rao K., Saha V. Medical management of Aspergillus flavus endocarditis. Pediatr Hematol Oncol 2000, 17(5):425-427.
55. Rudramurthy S.M., et al. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis 2011, 71(4):370-377.
56. Slaven J.W., Anderson M.J., Sanglard D., Dixson G.K., et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in itraconazole resistant clinical isolate. Fungal Genet Biol 2002, 36:199-206.
57. Saghrouni F., et al. Twenty-nine cases of invasive aspergillosis in neutropenic patients. Med Mal Infect 2011, 41(12):657-662.
58. Saito T., Shime N., Itoh K., Fujita N., Saito Y., Shinozaki M., et al. Disseminated aspergillosis following resolution of Pneumocystis pneumonia with sustained elevation of beta-glucan in an intensive care unit: a case report. Infection 2009, 37(6):547-550.
59. Seyedmousavi S., Meletiadis J., Melchers W.J., Rijs A.J., Mouton J.W., Verweij P.E. In vitro interaction of voriconazole combined with anidulafungin against triazole resistant Aspergillus fumigatus. Antimicrob Agents Chemother 2012.
60. Snelders E., Camps S.M., Karawajczyk A., Schaftenaar G., Kema G.H., van der Lee H.A., et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012, 7(3):e31801.
61. Snelders E., Melchers W.J., Verweij P.E. Azole resistance in Aspergillus: a new challenge in the management of invasive aspergillosis?. Future Microbiol 2011, 6(3):335-347.
62. St Georgiev V. Membrane transporters and antifungal drug resistance. Curr Drug Targets 2000, 1(3):261-284.
63. Tobin M.B., Peery R.B., Skatrud P.L. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene 1997, 200(1-2):11-23.
64. Van Der Linden J.W., Warris A., Verweij P.E. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol 2010.
65. Van Der Linden J.W., Snelders E., Kampinga G.A., Rijnders B.J., Mattsson E., Debets-Ossenkopp Y.J., et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011, 17(10):1846-1854.
66. Verweij P.E., van de Sande-Bruisma N., Kema G.H., Melchers W.J. Azole resistance in Aspergillus fumigatus in the Netherlands-increase due to environmental fungicides?. Ned Tijdschr Geneeskd 2012, 156(25):A4458.
67. Verweij P.E., Howard S.J., Melchers W.J., Denning D.W. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009, 12(6):141-147.
68. Verweij P.E., Mellado E., Melchers W.J. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 356(14):1481-1483.
69. Wang Q., Cui Z.F. Pleiotropic drug resistance ABC transporters in fungi. Yi Chuan 2011, 33(10):1048-1056.
70. Yuchong C., Dingheng Z., Zhizhong Y., Hongyu Y., Jing H., Jianghan C. Aspergillosis of biliary tract after liver transplantation: a case report. Mycopathologia 2010, 170(2):117-121.
71. Zaidan M., et al. Aspergillus-related myositis: a case report and review of the literature. Semin Arthritis Rheum 2011, 41(2):230-235.
72. Zhu L.P., et al. Aspergillus vertebral osteomyelitis and ureteral obstruction after liver transplantation. Transpl Infect Dis 2011, 13(2):192-199.